Envelope 1 Revenue and Competitors
Estimated Revenue & Valuation
- Envelope 1's estimated annual revenue is currently $1.7M per year.
- Envelope 1's estimated revenue per employee is $121,429
Employee Data
- Envelope 1 has 14 Employees.
- Envelope 1 grew their employee count by 27% last year.
Envelope 1's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP | Reveal Email/Phone |
2 | VP, Sales and Marketing | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Graphic Designer/ Prepress Manager | Reveal Email/Phone |
5 | ERP Project Manager | Reveal Email/Phone |
6 | National Business Development Manager | Reveal Email/Phone |
7 | Sales account and Customer management professional | Reveal Email/Phone |
8 | Inside Sales Account Manager | Reveal Email/Phone |
Envelope 1 Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 14 | 27% | N/A | N/A |
#2 | N/A | 40 | 14% | N/A | N/A |
What Is Envelope 1?
N/A
Total Funding
14
Number of Employees
$1.7M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Envelope 1 News
2022-04-20 - FDA Requests Comments on Potential Modification to Opioid Analgesic Risk
Evaluation and Mitigation Strategy
FDA notes that this is just one possible application of FDA's new ... with the mail-back envelope REMS requirement, including possibly: (1)...
2022-04-17 - Longtime Employee of a Harford County, Maryland ...
Urcioli would put a copy of the purchase order ticket in an envelope along with Employee 1's and Kleinman's share of the kickback amount...
2022-03-22 - Study shows that the SARS-CoV-2 envelope protein potently restricts HIV-1
infection
et al. (2022) "The Envelope Protein of SARS-CoV-2 Inhibits Viral Protein Synthesis and Infectivity of Human Immunodeficiency Virus type 1 (HIV-1)...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 14 | N/A | N/A |
#2 | $1.3M | 14 | N/A | N/A |
#3 | $1.8M | 14 | N/A | N/A |
#4 | $2.1M | 14 | N/A | N/A |
#5 | $1.2M | 14 | N/A | N/A |